Clinical trial
A Phase II Trial of Integrating Stereotactic Body Radiation Therapy With Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer
NCT02314364 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Trial of Integrating Stereotactic Body Radiation Therapy With Selective Targeted Therapy in Stage IV Oncogene-driven Non-Small Cell Lung Cancer
- Lead sponsor
- Massachusetts General Hospital
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- December 31, 2014
- Completion date
- October 25, 2023
- Enrollment
- 27 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
non-small cell lung cancer metastatic, targetable oncogenes (egfr, alk, ros1)